A carregar...

Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)

Respiratory syncytial virus (RSV) is a leading cause of hospitalization in children less than 1 year of age and causes substantial morbidity. Although there is not currently a vaccine available to prevent RSV infection, prophylaxis with the humanized monoclonal antibody palivizumab has been shown to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Geskey, Joseph M, Thomas, Neal J, Brummel, Gretchen L
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2007
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2721348/
https://ncbi.nlm.nih.gov/pubmed/19707346
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!